Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AbbVie
Woman Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain Estudio de extensión para evaluar la seguridad y la eficacia a largo plazo de elagolix en participantes con dolor de moderado a severo asociado a endometriosis
The primary objective of this 6-month extension study is to evaluate the continued safety, efficacy and tolerability of the 150 mg QD and 200 mg BID doses of elagolix (ABT-620) for up to 12 months in ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
AbbVie
Update Il y a 4 ans
Étude M16-300 : étude de phase 1/2 évaluant la sécurité et l’éfficacité du rovalpituzumab tesirine administré en association avec du nivolumab ou du nivolumab et de l’ipilimumab chez des patients ayant un cancer du poumon à petites cellules de stade avancé. [essai clos aux inclusions]
Le cancer du poumon à petites cellules prend naissance dans les cellules qui tapissent les bronches situées au centre des poumons. Il y a deux types principaux de cancer du poumon non à petites cellul...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalation
To compare the effectiveness based on the achievement of minimal disease activity (MDA) at Week 16 between subjects who had adalimumab introduced and those that had methotrexate (MTX) escalated to the...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Phase 1/2 Study of Venetoclax in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy
● The primary objectives of the Phase 1 portion are to assess the safety profile, characterize pharmacokinetics (PK), determine the dose schedule, the maximum tolerated dose (MTD), and the recommended...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
An Extension Study of Navitoclax (ABT-263) in Subjects with Chronic Lymphocytic Leukemia (CLL)
The primary objective is to assess the safety of navitoclax.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)
• To compare the efficacy of ABT-494 QD versus placebo, and versus adalimumab (ADA) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in subjects with moderately to severely active ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
Phase 2, Single-Arm, Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5
Assess the safety and tolerability of risankizumab in PsA subjects who have completed all doses of study drug and the Week 24 visit in Study 1311.5.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AbbVie Deutschland GmbH & Co. KG
Update Il y a 4 ans
An open-label study to evaluate the safety and efficacy of three experimental drugs (Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir) in people with genotype 1b hepatitis C virus (HCV) and early liver damage. "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objectives of this study are to compare the efficacy (the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [HCV RNA < lower limit of quantification (LLOQ) 12 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
5
6
7
8
9
10
11
12
13
14